All News
Filter News
Found 808,679 articles
-
All Physicians In Switzerland Are Now Able To Prescribe Sucampo Pharmaceuticals, Inc.'s AMITIZA® For Chronic Idiopathic Constipation
2/6/2014
-
Janssen Pharmaceutical Inc. 's ZYTIGA® Now Reimbursed in Quebec For Use Prior To Chemotherapy In Men With Metastatic Prostate Cancer
2/6/2014
-
St. Jude Medical Announces First U.S. Patient Implant Of Non-Surgical, Leadless Cardiac Pacemaker
2/6/2014
-
InControl Medical LLC Ships First International Order To Ireland For Non-Surgical, Drug Free Treatment Of Female Incontinence
2/6/2014
-
Coronado Biosciences Granted A Second Key Patent For CNDO-109, An Activator Of Natural Killer Cells
2/6/2014
-
Sialix Closes Oversubscribed Second Tranche Of Series B Financing
2/6/2014
-
TNG Pharmaceuticals, Inc. Closes $4.6 Million Series A Financing
2/6/2014
-
Novelos Therapeutics, Inc. Announces Definitive Agreements To Raise $4.0 Million In Private Placement Of Convertible Debentures And Warrants
2/6/2014
-
Egalet Announces Pricing Of Initial Public Offering
2/6/2014
-
Celsus Therapeutics Announces The Closing Of $9.2 Million Public Offering And Full Exercise Of Underwriter's Option To Purchase Additional Adss
2/6/2014
-
AFcell Medical Changes Its Name To Liventa Bioscience
2/6/2014
-
RBCC Seeks Out Capital Partners For 3D Bioprinting Expansion
2/6/2014
-
Miraculins Inc. Release: Diabetes In China: Canadian Biotech Aims To Make A Difference
2/6/2014
-
GenomOncology To Enable CompanionDx Clinical Cancer Panels
2/6/2014
-
W. L. Gore & Associates, Inc. Launches Expanded Treatment Portfolio Featuring Lower Profile GORE® EXCLUDER® AAA Endoprosthesis In Australia And New Zealand
2/6/2014
-
Mirus Transfectopedia™: Mirus Bio LLC Announces A New In-depth Transfection Resource Guide
2/6/2014
-
Trevena, Inc. Announces Closing Of Initial Public Offering
2/6/2014
-
Mela Sciences Completes Private Placement To Institutional Investors And MELA Sciences Directors
2/6/2014
-
Coldstream Laboratories Inc. Announces Key Quality Certifications For Team Members
2/6/2014
-
Ultragenyx Pharmaceuticals Announces Closing Of Initial Public Offering And Exercise Of Underwriters' Option To Purchase Additional Shares
2/6/2014